The FDA approved daraxonrasib, sold as Rasonque by Revolution Medicines, as a daily oral treatment for pancreatic cancer after a trial showed median overall survival of 13.2 months versus 6.7 months with chemotherapy. The American Cancer Society projects 67,000 new U.S. cases and more than 52,000 deaths this year, with a 13% five-year survival rate. Unverified reports link the drug to former Senator Ben Sasse and include physician statements on its impact.